Webinar: Future of life sciences regulation
How industry, regulators, and patients can succeed together?
March 20 | 15:00 GMT
In an era of exponential changes in medicine, science and technology, life sciences regulation is evolving rapidly, as is its potential to add strategic value at the centre of the organisation.
Following the launch of our life
- how convergence and consistency of regulation is improving the efficiency and cost-effectiveness of regulation
- regulatory functions as a strategic asset and approaches to optimise collaboration with regulators
- how new data-driven approaches are enabling faster regulatory approvals, better sharing of risk and value to patients
- how advances in technologies and robotics are driving productivity and quality of regulation.
Upcoming chair of National Cancer Research Institute (NCRI) Consumer Forum, Member of Head and Neck Euracan
Emma brings with her a wealth of experience in galvanising patient involvement in research. Emma founded a London based Head and Neck cancer support group and is currently expanding her activities to set up a charity focused on rare salivary gland cancers. She is a member of the Head and Neck EURACAN domain and the NIHR Health Technology Assessment Prioritisation Committee B. Emma has also been an NCRI consumer representative on the NCRI Head and Neck Clinical Studies Group for the last four years.
Director Europe & International Regulatory Policy, Worldwide Regulatory Affairs at Pfizer
Julie is a regulatory affairs professional specialising in international regulatory policy with impact to innovative medicines. She specialises in advancing science-based regulatory policy, including in the area of regulatory system strengthening. In her role, she implements strategic regulatory policy initiatives and develops recommendations to address regional regulatory policy challenges. She holds a Ph.D. in immunology and vaccine development from Trinity College Dublin.
Vada A. Perkins
Head, Regulatory Intelligence Director, Regulatory Policy & Intelligence, Bayer Pharmaceuticals
Vada Perkins is a head of regulatory policy & intelligence at Bayer Pharmaceuticals and also a managing principal of IDENTIFICA. He is a former FDA Senior Advisor for Regulatory Science and a recognized global regulatory policy & intelligence expert with thought leadership in the application of data governance, technology, and international standards to regulatory science and informatics initiatives. His expertise in regulatory science supports proactive collaboration with national and international stakeholders to harmonize regulatory activities in the development of innovative approaches to better assess the safety, efficacy, quality, and performance of medicinal products worldwide. He has received numerous awards which includes the FDA Commissioner’s Special Citation. Mr Perkins received his degrees from Johns Hopkins University, University of Southern California, and the University of Maryland-Baltimore.
Partner, Monitor Deloitte
Hanno is a Partner at Monitor Deloitte, our strategy consultancy business. He has more than 20 years of consulting experience primarily in the Healthcare and Life Sciences sector. Hanno leads the Life Sciences and Healthcare team in Monitor Deloitte and is responsible for building the Real World Evidence capability within that.
Director, Deloitte Centre for Health Solutions
Karen is the Research Director of the Centre for Health Solutions. She supports the Healthcare and Life Sciences practice by driving independent and objective business research and analysis into key industry challenges and associated solutions. Karen also produces a weekly blog on topical issues facing the healthcare and life science industries.